Niraparib with abiraterone acetate and prednisone for metastatic castration resistant prostate cancer

Niraparib with abiraterone acetate and prednisone (AAP) is in clinical development for patients with prostate cancer which has spread from its original site (metastatic) and is untreatable via testosterone suppression therapy (castration resistant). Prostate cancer is a cancer of the prostate gland (a small organ in a man’s pelvis) and is the most common cancer in men in the UK. The symptoms may vary depending on the stage of cancer but can include pain, tiredness, and problems emptying the bladder and the bowels. The castration-resistant form of metastatic prostate cancer is particularly dangerous and leads to a very poor prognosis, hence additional treatment options are needed.